Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Status Report on Six Key R&D Programs
Lexaria announced significant strides in six of its studies within the 2021 applied R&D programAll the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertensionThe 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but also foster strategic commercial opportunities and corporate relationships Lexaria Bioscience (NASDAQ: LEXX)…